abstract: UNASSIGNED: 8019 Background: ASCT is the procedure of choice in poor risk NHL, however conditioning regimens is a challenging procedures because safely delivered only in younger and clinically fit @entity1 , thus new approaches are suggested to enhance its applicability. To extend the probability of cure to pts not eligible to standard ASCT from 12/2003 to 7/2007, 60 high-risk @entity2225 + NHL pts have been included in a phase II study with myeloablative Y90-Ibritumomab Tiuxetan, supported by ASCT. METHODS: @entity2225 + relapsed/refractory or newly diagnosed high-risk NHL adults defined by @entity22739 DLBCL, @entity11708 or transformed BCL, with no upper limit of age not eligible to standard ASCT have been enrolled. Pts were required to collect >= 9 x 10(6) @entity2280 +cells/kg. Y90-Ibritumomab Tiuxetan (0.8-1.2 mci/kg) was administered after rituximab based HDCT: DHAP x 3, CTX 5-7g/mq followed stem cells collection, @entity2592 12-24 g/mq with 2x10(6) @entity2280 (+) cells/kg support. To hasten hematopoietic recovery, each pt received two stem-cell autograft of 2x10(6) @entity2280 (+) cells/kg on day +7 and of >= 5x10(6) @entity2280 (+) cells/kg on day +14 from RIT. Rationale of the procedure have been published elsewhere (Devizzi: JCO 2008). RESULTS: Characteristics: M/F: 38/22; median age 63 (26-76); median comorbidities: 2 (1-3); Stage III-IV: 54; BM+: 36; newly high-risk NHL: 20; relapsed/refractory DLBC: 5/7; relapsed FCL/MZL 16/6; relapsed @entity11708 : 6; molecular probe: 47. All pts received PCR - autograft. Fifty-two pts reached CR (87%), 3 GPR (5%) 5 @entity1726 (8%). Grade 3-4 @entity1398 and @entity882 was 37% and 70% with a median duration of 2 and 4 days. Non hemathological @entity137 was: 4 @entity55 (6%); 2 @entity13443 (3%); 7 @entity2834 /HVZ reactivations (11%); One @entity204 occurred one month after transplant for VOD. Four pts developed sMDS/AML. With a median follow-up of 57 months 36 pts are in CCR, 18 pts relapsed, and 43 pts are still alive; the 5-year PFS and @entity3012 are 60% and 72% respectively. CONCLUSIONS: High dose(90)Y ibritumomab tiuxetan is an innovative, highly effective and tolerable myeloablative regimen. The incidence of sMDS/AML is similar to that observed with standard CT-based conditioning. Its use is strongly suggested in pts not eligible for standard ASCT.

title: Use of myeloablative Y90-ibritumomab tiuxetan in XXXX with high-risk @entity2225 + NHL not eligible for standard ASCT: Five-year results.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE: The purpose of this study was to compare the clinical outcomes of immediate rotator cuff repair with capsular release and those of rotator cuff repair after the @entity2693 was treated with rehabilitative therapy. METHODS: Between June 2007 and December 2010, we recruited 63 @entity1 with rotator cuff tears and @entity2693 . In 33 @entity1 arthroscopic rotator cuff repair was performed with capsular release simultaneously (group I). In 30 @entity1 arthroscopic rotator cuff repair was performed after 6 months of preoperative rehabilitation for @entity2693 (group II). The American Shoulder and Elbow Surgeons score, Simple Shoulder Test score, Constant score, and visual analog scale score for @entity158 and range of motion (ROM) were assessed at the start of the study; at 3, 6, and 12 months; and at the last visit. The postoperative cuff tendon integrity was assessed between 6 and 12 months using magnetic resonance or ultrasound images. RESULTS: There were no significant differences in preoperative demographic data between the groups (P > .05). The mean follow-up period was 21.54 months. After treatment, there was significant improvement in ROM and functional scores in both groups, as measured at the last follow-up (P < .05). No statistical differences were found in clinical scores and ROM at the last follow-up (P > .05). On assessment of the magnetic resonance or ultrasound images taken 6 to 12 months postoperatively, the retear rate for the repaired cuff tendon in each group was 12.1% in group I and 13.4% in group II. CONCLUSIONS: In the treatment of rotator cuff tears with @entity2693 , satisfactory results can be achieved either by repairing the tear with simultaneous capsular release or by waiting to perform the repair after preoperative rehabilitation for @entity2693 . Because a delayed rotator cuff repair after improving ROM offered no clear advantage over an immediate operation, we recommend surgically treating rotator cuff tears with concomitant @entity2693 early using a simultaneous capsular release method to save time and to avoid unnecessary rehabilitation. LEVEL OF EVIDENCE: Level II, prospective comparative study.

title: Are Delayed Operations Effective for XXXX With Rotator Cuff Tears and Concomitant Stiffness? An Analysis of Immediate Versus Delayed Surgery on Outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2693 :: ('MESH:C566112', 'Disease') :: ['stiffness']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: BACKGROUND: This clinical trial evaluated whether @entity1945 in combination with bevacizumab improved progression-free survival (PFS) in @entity1 with advanced, @entity1149 in a second-line setting. @entity1 AND METHODS: @entity1 aged 18 years old and older received @entity1945 (4.0 mg/m(2)) on days 1, 8, and 15, and bevacizumab (10 mg/kg) on days 1 and 15 as intravenous infusions on a 28-day treatment cycle. Available @entity5 specimens were analyzed for @entity29459 gene expression as a biomarker of response to @entity1945 . RESULTS: Forty-two @entity1 were enrolled in the study, with a median age of 62.5 years and a median of 3 (range, 1-7) prior treatment regimens. Almost half (n = 18, 42.9%) of the @entity1 received prior bevacizumab therapy. PFS was 5.1 months (95% CI, 3.7-7.8 months), and overall survival was 11.5 months (95% CI, 6.8-15.5 months). Response rates were as follows: 14.3% partial response, 54.8% stable disease, and 28.6% progressive disease. Hematologic toxicities included grade 3 @entity882 (n = 7, 16.7%), @entity1398 (n = 4, 9.5%), and @entity417 (n = 2, 4.8%). One @entity137 occurred due to @entity548 , and one @entity1 experienced a grade 4 @entity1151 . Grade 3 nonhematologic adverse events were uncommon (< 8%). There was a trend for improved median PFS, 3.5 months vs. 1.8 months (P = .26), in @entity1 with high @entity29459 expression. CONCLUSION: Bevacizumab in combination with @entity1945 as a salvage therapy for metastatic non--small-cell @entity2 is well tolerated and is worthy of further investigation.

title: Phase II study of XXXX and bevacizumab in advanced, @entity1149 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENT']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxic death']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['pulmonary hemorrhage']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['refractory non--small-cell lung cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism']

entities_list: @entity1945 :: ('MESH:D019772', 'Chemical') :: ['topotecan']

answer: @entity1945 :: (MESH:D019772,Chemical) :: ['topotecan']


abstract: @entity32 with pontine perivascular enhancement responsive to @entity230 (CLIPPERS) is a rare central nervous system inflammatory disease characterized by the punctate @entity2287 enhancement peppering the pons and the cerebellar peduncles as neuroimaging. We report the case of a 66-year-old @entity1 who presented with CLIPPERS associated with swelling in the brainstem. She was hospitalized because of gait @entity2055 and @entity1662 disturbance. MRI of the brain showed FLAIR hyperintense lesions in the pons, cerebellar peduncles, cerebellum and the subcortical @entity62 in the right occipital lobe with significant swelling in the brainstem. Diffusion-weighted MRI did not show an abnormal signal, indicating vasogenic @entity4 . Post-contrast T1-weighted MRI showed enhanced area in the right occipital lobe and panctate @entity2287 enhancement peppering brainstem. Treatment with @entity230 led to rapid improvement. However, she showed exacerbation of clinical and radiological findings during the tapering schedule of @entity134 . The biopsy from the occipital lobe revealed intense perivascular and parenchymal lymphocytic infiltrates composed of primarily T cells, B cells and macrophages. The @entity1 was diagnosed with CLIPPERS, and treatment with increased dose of corticosteroid induced a clinical improvement. Previous reports well described a characteristic MRI finding of punctate enhancement peppering the pons. In addition, the pons and cerebellar peduncles swelling can occur in this disorder.

title: [ XXXX with pontine perivascular enhancement responsive to @entity230 (CLIPPERS) associated with swelling in the brainstem: a case report].

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['Chronic lymphocytic inflammation']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity1662 :: ('MESH:D003244', 'Disease') :: ['consciousness']

entities_list: @entity62 :: ('MESH:D056784', 'Disease') :: ['white matter lesion']

entities_list: @entity2287 :: ('MESH:D005682', 'Chemical') :: ['gadolinium']

answer: @entity32 :: (MESH:D007249,Disease) :: ['Chronic lymphocytic inflammation']


abstract: Among @entity1 with @entity7288 after cesarean section, a double-blind comparison of @entity3402 - @entity801 versus @entity5503 -placebo therapy was performed. Study criteria were: exclusion--use of prophylactic antibiotics or @entity566 to the drugs used; entry--uterine tenderness, oral temperature greater than or equal to 101 degrees F, and @entity491 . Uterine specimens for culture were obtained via a single-lumen transcervical catheter. Most common isolates were Bacteroides bivius, @entity526 , and anaerobic cocci. @entity2259 occurred in 9.0%. Therapy results were: [Chart: see text]. Therapeutic failures were defined as persistent @entity221 despite 3 or more days of treatment. Among the six @entity3402 - @entity801 therapeutic failures, one @entity1 had a resistant organism, and one had a pelvic mass. Among the 13 @entity5503 -placebo therapeutic failures, three @entity1 had resistant organisms, and one had a pelvic mass. Cause of persistent @entity221 was not evident in the other @entity1 . Side effects that necessitated discontinuation of therapy were: @entity3402 - @entity801 group-- @entity294 (six), @entity56 response (one); @entity5503 -placebo group-- @entity294 (two), @entity56 response (one). If the common practice of excluding side-effect failures is followed, there were more cures in the @entity3402 - @entity801 group (P = 0.06).

title: A double-blind, randomized comparison of @entity3402 - @entity801 versus XXXX for treatment of post-cesarean section @entity7288 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity801 :: ('MESH:D005839', 'Chemical') :: ['gentamicin']

entities_list: @entity5503 :: ('MESH:D002435', 'Chemical') :: ['cefamandole']

entities_list: @entity7288 :: ('MESH:D004716', 'Disease') :: ['endomyometritis']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic']

entities_list: @entity2259 :: ('MESH:D016470', 'Disease') :: ['Bacteremia']

entities_list: @entity491 :: ('MESH:D007964', 'Disease') :: ['leukocytosis']

entities_list: @entity3402 :: ('MESH:D002981', 'Chemical') :: ['clindamycin']

answer: @entity5503 :: (MESH:D002435,Chemical) :: ['cefamandole']


abstract: T cells expressing the Vgamma4 T-cell receptor (TCR) promote @entity2401 in coxsackievirus B3 (CVB3)-infected BALB/c @entity19 . @entity2659 , a major histocompatibility complex (MHC) class I-like molecule, is required for activation of Vgamma4(+) cells. Once activated, Vgamma4(+) cells initiate @entity2401 through @entity60 )-mediated induction of @entity1961 (+) T helper type 1 (Th1) cells in the infected animal. These @entity1961 (+) Th1 cells are required for activation of an autoimmune CD8(+) alphabeta TCR(+) effector, which is the predominant pathogenic agent in this model of CVB3-induced @entity2401 . Activated Vgamma4(+) cells can adoptively transfer @entity2401 into BALB/c @entity19 infected with a nonmyocarditic variant of CVB3 (H310A1) but cannot transfer @entity2401 into either uninfected or @entity2659 (-/-) recipients, demonstrating the need for both infection and @entity2659 expression for Vgamma4(+) cell function. In contrast, CD8(+) alphabeta TCR(+) cells transfer @entity2401 into either infected @entity2659 (-/-) or uninfected recipients, showing that once activated, the CD8(+) alphabeta TCR(+) effectors function independently of both virus and @entity2659 . Vgamma4(+) cells given to @entity19 lacking @entity1961 (+) T cells minimally activate the CD8(+) alphabeta TCR(+) cells. These studies show that Vgamma4(+) cells determine CVB3 pathogenicity by their ability to influence both the @entity1961 (+) and CD8(+) adaptive immune response. Vgamma4(+) cells enhance @entity630 ( @entity60 (+)) cell activation through @entity60 - and @entity2659 -dependent mechanisms. @entity1961 (+) Th1 cells promote activation of the autoimmune CD8(+) alphabeta TCR(+) effectors.

title: Vgamma4(+) T cells promote autoimmune CD8(+) cytolytic T-lymphocyte activation in coxsackievirus B3-induced @entity2401 in @entity19 : role for XXXX (+) Th1 cells.

entities_list: @entity60 :: ('15978(Tax:10090)', 'Gene') :: ['IFN-gamma', 'gamma interferon (IFN-gamma']

entities_list: @entity2401 :: ('MESH:D009205', 'Disease') :: ['myocarditis']

answer: @entity1961 :: (12504(Tax:10090),Gene) :: ['CD4']


abstract: AIMS: @entity1540 ( @entity1540 ) originating from the right ventricular outflow tract (RVOT) may occasionally trigger @entity1165 ( @entity1165 ), polymorphic @entity1165 (PVT), or @entity2224 ( @entity2224 ). We examined whether an analysis of the ventricular repolarization instability could differentiate PVT/ @entity2224 triggered by @entity1540 from benign @entity1540 or @entity1165 . METHODS: We evaluated the ventricular repolarization instability as assessed by the beat-to-beat T-wave amplitude variability ( @entity16491 ) using Holter recordings in @entity1 with @entity1540 but with no structural @entity299 . We determined the prematurity index, defined as the ratio of the coupling interval of the first @entity1165 ( @entity1165 ) beat or isolated PVC to the preceding R-R interval just before the @entity1165 or isolated PVC in the Holter recordings. The study @entity1 were classified into @entity1540 / @entity1165 (n = 33) and PVT/ @entity2224 (n = 10). RESULTS: The two groups did not differ with respect to the age, sex, and left ventricular ejection fraction. There was no significant difference in the prematurity index between the two groups ( @entity1540 / @entity1165 0.66    0.16 vs. PVT/ @entity2224 0.61    0.13, P = 0.60). The @entity1 with PVT/ @entity2224 had a significantly larger maximum @entity16491 than those with @entity1540 / @entity1165 (31    13 vs. 68    40   V, P < 0.001). @entity1 with a higher than median value of the @entity16491 (33   V) were at increased risk of PVT/ @entity2224 vs. those with a lower than median value, after adjusting for the age and sex [9.25 (95% confidence interval: 1.27-19.2); P = 0.03]. CONCLUSIONS: The @entity16491 analysis is a useful measure to identify the subset of usually benign RVOT-PVC/ @entity1165 @entity1 prone to PVT/ @entity2224 .

title: Beat-to-beat T-wave amplitude variability in the risk stratification of right ventricular outflow tract-premature ventricular complex XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['monomorphic ventricular tachycardia', 'VT', 'ventricular tachycardia', 'MVT']

entities_list: @entity2224 :: ('MESH:D014693', 'Disease') :: ['VF', 'ventricular fibrillation']

entities_list: @entity1540 :: ('MESH:D018879', 'Disease') :: ['Premature ventricular complexes', 'RVOT-PVCs', 'PVCs']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: In clinical practice, most @entity1 with @entity1149 ( @entity1149 ) who respond to @entity669 kinase inhibitors eventually progress because of an acquired resistance mutation, @entity9513 , in @entity470 ( @entity470 ). Thus, it is important to identify a new drug to reduce resistance. The aim of this study was to test whether @entity670 combined with @entity4562 is effective against @entity1149 in a cell line carrying @entity9513 , and to clarify the underlying mechanisms. The @entity1 @entity2 cell line H1975 was used as an in vitro and in vivo model. Cells were treated with @entity4562 , @entity670 , or a combination at a range of concentrations. Cell proliferation was calculated to assess the anticancer effects of the compounds in vitro. Flow cytometry and Western blotting were employed to determine the inhibitory effects on proliferation and the induction of apoptosis. The in vivo effects of the compounds were examined using a xenografted nude @entity19 model for validation. @entity4562 together with @entity670 enhanced both growth inhibition and apoptosis; however, the greatest synergistic effect was observed at low concentrations. p- @entity470 , p-Akt, and p- @entity3470 expressions in vitro were reduced more by the combined use of the drugs, whereas @entity522 and @entity12982 activities were increased. Significantly more @entity5 growth inhibition was detected following combination treatment in the in vivo model. These findings suggest that @entity670 enhanced the antitumor effects of @entity4562 in a @entity1149 cell line carrying the @entity9513 mutation. This synergistic activity may be due to increased inhibition of the downstream molecular and pro-apoptotic effects of @entity470 .

title: Synergistic inhibitory effects by the combination of @entity4562 and @entity670 on XXXX with acquired drug-resistance in vitro and in vivo.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity4562 :: ('MESH:C419708', 'Chemical') :: ['gefitinib', 'Gefitinib']

entities_list: @entity670 :: ('MESH:D019833', 'Chemical') :: ['genistein']

entities_list: @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non small cell lung cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['NSCLC']


abstract: There is now substantial evidence that @entity2438 in the general population lie on a continuum, with clinical @entity72 ( @entity72 ) representing the extreme end of this distribution. In this study, we sought to evaluate five independently identified genetic associations with @entity72 with @entity2438 in the general population. In the study cohort, clinical phenotype and genomewide association genotype data were obtained from the Western Australian Pregnancy Cohort (Raine) Study. The outcome measure used was the Autism Spectrum Quotient (AQ), a quantitative measure of @entity2438 of individuals in the cohort. Total AQ scores were calculated for each individual, as well as scores for three subscales. Five candidate single nucleotide polymorphism (SNP) associations with @entity72 , reported in previously published genomewide association studies, were selected using a nominal cutoff value of P less than 1.0*10. We tested whether these five SNPs were associated with total AQ and the subscales, after adjustment for possible confounders. SNP @entity57411 located in the @entity41677 ( @entity41677 ) gene was significantly associated with the Communication/Mindreading subscale. No other SNP was significantly associated with total AQ or the subscales. The @entity41677 gene is a strong positional candidate risk factor for @entity2438 in the general population.

title: @entity41677 gene associated with XXXX in a general population sample.

entities_list: @entity41677 :: ('140733', 'Gene') :: ['macro domain containing 2', 'MACROD2']

entities_list: @entity72 :: ('MESH:D002659', 'Disease') :: ['ASD', 'autism spectrum disorders']

entities_list: @entity2438 :: ('MESH:D001321', 'Disease') :: ['autistic-like traits']

answer: @entity2438 :: (MESH:D001321,Disease) :: ['autistic-like traits']


abstract: In a retrospective study of invasive @entity7135 in Greater Gothenburg, Sweden, 213 cases of culture-verified @entity693 or @entity295 were identified during the 15-year period 1975-1989. The annual incidence was 2.0/100,000. Cases were seen in all age-groups with the highest rates in the 0-4 and 15-19 year-old groups, 9.5 and 6.2/100,000 respectively. 20% of the @entity1 were less than 2 years. 91% of the @entity1 had no known risk factors. In only 10 cases (5%) was contact with another case of @entity7135 known. The main clinical manifestations were @entity693 (57%), @entity295 with no sign of @entity8796 (25%) and @entity326 (17%). The case-fatality rate for all the @entity1 was 6.6% and did not change during the 15-year period. One-third of the @entity1 who presented with @entity326 died. The serogroup was known for strains from 192 @entity1 . 51% of the strains belonged to serogroup B, 10% to group A and 23% to group C. In conclusion, the incidence of @entity7135 was low but the relatively high case-fatality rate warrants a search for effective prophylaxis. About 30% of the cases were potentially preventable by the currently available tetravalent (A, C, Y and W135) polysaccharide vaccine, which is immunogenic in @entity1 greater than 2 years. Widespread use of antibiotic prophylaxis to close contacts of known cases would not lower the incidence markedly.

title: Incidence, serogroups and case-fatality rate of invasive XXXX in a Swedish region 1975-1989.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity295 :: ('MESH:D018805', 'Disease') :: ['septicaemia']

entities_list: @entity326 :: ('MESH:D012772', 'Disease') :: ['septic shock']

entities_list: @entity693 :: ('MESH:D008581', 'Disease') :: ['meningitis']

entities_list: @entity8796 :: ('MESH:D005490', 'Disease') :: ['focal infection']

entities_list: @entity7135 :: ('MESH:D008589', 'Disease') :: ['meningococcal infection', 'meningococcal infections']

answer: @entity7135 :: (MESH:D008589,Disease) :: ['meningococcal infections']


abstract: INTRODUCTION: @entity5 of the oesophagus is a major problem in Yemen, where most of the @entity1 present with advanced disease. Curative oesophageal resection for @entity189 may be carried out by either the transhiatal or transthoracic technique. The aims of this study were to compare the morbidity, mortality, short term outcome and long term survival of the two techniques in the treatment of @entity189 . METHODS: From March 1998 to July 2004,118 @entity1 with @entity5 of the oesophagus were studied. The @entity5 in 84 @entity1 were resected by transhiatal oesophagectomy (43) and transthoracic oesophagectomy (41). RESULTS: The two groups were comparable in terms of age, sex, location of the @entity5 , risk factors and stage of the disease. There was no significant difference in the mean intensive care unit stay, blood transfusion and mean hospital stay. @entity834 was higher in the transhiatal oesophagectomy group than transthoracic group (21 percent versus 12 percent, p-value is equal to 0.001). Recurrent @entity66 was present in 18.6 percent of the transhiatal group and absent in the transthoracic group. The overall hospital mortality was 8.3 percent with no significant difference between the two groups (transhiatal 9.3 percent versus transthoracic 7.3 percent, p-value is equal to 0.742). CONCLUSION: Transhiatal oesophagectomy was associated with a higher incidence of @entity532 and recurrent @entity66 , but there was no significant difference in the mortality between the two groups.

title: Transhiatal versus transthoracic resection for XXXX in Yemen.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity834 :: ('MESH:D057868', 'Disease') :: ['Anastomotic leak']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['laryngeal nerve lesions', 'laryngeal nerve lesion']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumours', 'Cancer']

entities_list: @entity532 :: ('MESH:D003925', 'Disease') :: ['anastomotic complications']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma', 'oesophageal carcinoma']

answer: @entity189 :: (MESH:D002277,Disease) :: ['oesophageal carcinoma']


abstract: UNASSIGNED: The @entity267 protects the anterior eye and accounts for two thirds of the eyes refractive capacity. The homeostasis of corneal epithelium is thought to be maintained by putative stem cells residing in the epithelial basal layer. As a tissue constantly exposed to environmental stress, the @entity267 is hypothesised to accumulate persistent DNA damage events with time in stem cell populations. Recently, telomere associated DNA damage foci (TAFs) have been suggested as a marker for persistent DNA damage which can be used to detect senescent cells during ageing. Dietary restriction (DR) is the only known non-genetic intervention that is able to increase both life and health span among various animal species. The aim of this study was to analyse changes in corneal properties with age and under 16months of DR. We employed immunofluorescence staining for   @entity2006 together with telomere fluorescence in situ hybridisation (immuno-FISH) on @entity19 corneas from young, old ad libitum (AL) fed as well as dietary restricted (DR) @entity19 . Our data show that the central corneas of old @entity19 had significantly more general and telomere-associated DNA damage compared to young @entity19 while DR treatment was able to reduce the amount of DNA damage significantly. We also found that the thickness of the peripheral region of the @entity267 , where the putative stem cells may reside, decreased with age regardless of whether the animals underwent DR treatment or not. Number of bullae, which indicates @entity3279 , accumulated in old corneas in the central area and DR treatment mitigated the formation of these bullae. Moreover, the protein levels of the stem cell marker TAp63 decreased with age only in the central but not the peripheral region of the @entity267 . This finding suggests that epithelial progenitors might be better maintained in the peripheral than the central @entity267 during ageing. Together with the finding that the peripheral corneal showed no increase in DNA damage during age, we speculate that in @entity19 , like @entity1 , the putative stem cells reside in the peripheral @entity267 .

title: Dietary restriction mitigates age-related accumulation of DNA damage, but not all changes in XXXX corneal epithelium.

entities_list: @entity3279 :: ('MESH:D015715', 'Disease') :: ['corneal edema']

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: Diffuse @entity11 is a rare disease in adults. Radiotherapy (RT) is usually considered to be the standard treatment. However, the role of chemotherapy in treating relapses after RT is unclear, and this study aimed to assess the use of @entity2903 ( @entity2904 ) in this situation. We conducted a retrospective analysis of @entity1 from our database with "low grade" adult diffuse infiltrating @entity11 who received @entity2904 at relapse after failing RT. The @entity1 were diagnosed by histology or MRI criteria compatible with a @entity11 . The @entity5 were localized in the pons, medulla oblongata or midbrain, excluding supratentorial or @entity5 that had infiltrated the brainstem secondarily. The @entity1 ' clinical and radiological responses were assessed, and their progression free survival (PFS) and overall survival (OS) time were estimated. Fifteen adult @entity1 (median age 34  years) fulfilled the inclusion criteria. Histological analysis was available in 5 cases and showed grade II @entity3271 (2 cases), grade II @entity816 (2 cases), and grade II @entity816 (1 case). Ten @entity1 were selected by MRI criteria only. All @entity1 received RT as initial treatment and had a median PFS of 34.2  months (95  % CI 24.1-44.2). The median KPS at the time of relapse was 80. @entity2904 was administered orally at 150-200  mg/m(2) for 5  days, every 28  days. Clinical improvement after @entity2904 was observed in 9 cases (60  %), whereas radiological assessment detected responses in 6/15 cases, including 4 partial and 2 minor responses. The estimated median PFS after @entity2904 was 9.5  months (95  % CI 7.9-11), and the median OS was 14.4  months (95  % CI 10.5-18.2). Grade 3 @entity882 was observed in 26  % of cases. @entity2904 could be useful after RT failure in adult @entity1 with recurrent diffuse "low grade" @entity11 .

title: @entity2903 after radiotherapy in recurrent "low grade" diffuse XXXX in adults.

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombopenia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['infratentorial tumors', 'tumors']

entities_list: @entity11 :: ('MESH:D005910', 'Disease') :: ['brainstem glioma', 'low-grade glioma']

entities_list: @entity816 :: ('MESH:D001254', 'Disease') :: ['oligoastrocytoma', 'astrocytoma']

entities_list: @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide']

entities_list: @entity3271 :: ('MESH:D009837', 'Disease') :: ['oligodendroglioma']

answer: @entity11 :: (MESH:D005910,Disease) :: ['brainstem glioma']


abstract: BACKGROUND AND PURPOSE: @entity1274 ( @entity1274 ) is a common complication to radiation therapy in the upper head and neck region. In this study, we estimated the dose response relationship for @entity1274 with adjustment for pre-therapeutic risk factors. @entity1 AND METHODS: The pre- and post-therapeutic hearing levels were recorded in a previously published study of 20 @entity1 receiving radiotherapy for @entity189 . In the present study, the dose to the inner ear of these @entity1 was estimated with a computed tomography (CT) based treatment planning system. CT data from a 'proxy @entity1 ' were used for @entity1 with no available CT scan. @entity1274 was analyzed as a function of radiation dose and potential risk factors were tested. RESULTS: The incidence of @entity1274 increased significantly with increasing dose to the cochlea. Increasing @entity1 's age, and decreasing pre-therapeutic hearing level were statistically significantly associated with an increased risk of @entity1274 . A nomogram is presented for estimating individualized dose constraints of potential use in treatment planning. CONCLUSIONS: The inner ear is a critical structure in @entity1 with @entity189 and the dose to the inner ear should be carefully considered when planning radiation treatment in this region.

title: @entity1274 after radiotherapy for XXXX : individualized risk estimation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity1274 :: ('MESH:D006319', 'Disease') :: ['Sensori-neural hearing loss', 'SNHL']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['nasopharyngeal carcinoma']

answer: @entity189 :: (MESH:D002277,Disease) :: ['nasopharyngeal carcinoma']


abstract: PURPOSE: Despite clinical evidences that @entity1375 is often associated with @entity73 , @entity1316 and @entity716 , the effects of @entity1374 on the adult brain have been largely unexplored. We investigated the hypothesis that @entity1375 might affect cortical @entity2146 and modulates inhibitory and excitatory cortical circuits by using Transcranial Magnetic Stimulation. MATERIALS AND METHODS: Cortical @entity2146 was probed in 10 @entity1 with @entity1375 and 10 age-matched healthy controls. We tested motor thresholds and corticospinal @entity2146 , cortical silent period and peripheral silent period, short interval intracortical inhibition, intracortical facilitation. @entity1 were evaluated at the time of diagnosis, as well as after 3 and 6 months replacement therapy with l-thyroxin. RESULTS: At baseline, @entity1 showed decreased cortical @entity2146 , with increased resting and active motor threshold and decreased steepness of the motor evoked potential recruitment curves. These changes were paralleled by longer cortical silent period and decreased short interval intracortical inhibition. After 3 months replacement therapy, all the parameters but short interval intracortical inhibition were restored to normal values. Short interval intracortical inhibition returned to normal values only after 6 months of replacement therapy. CONCLUSIONS: Thyroid hormones are needed to modulate cortical @entity2146 and cortical inhibitory circuits in adults.

title: Neural response to transcranial magnetic stimulation in XXXX and effect of replacement treatment.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1375 :: ('MESH:D007037', 'Disease') :: ['overt hypothyroidism', 'hypothyroidism']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive dysfunction']

entities_list: @entity1316 :: ('MESH:D019964', 'Disease') :: ['affective disorders']

entities_list: @entity2146 :: ('MESH:D011595', 'Disease') :: ['excitability']

entities_list: @entity716 :: ('MESH:D011605', 'Disease') :: ['psychosis']

entities_list: @entity1374 :: ('MESH:D013959', 'Disease') :: ['thyroid hormone deficiency']

answer: @entity1375 :: (MESH:D007037,Disease) :: ['adult hypothyroidism']


abstract: Antimicrosomal antibodies in @entity409 all seem to be directed against members of the @entity12325 family of proteins. These autoantigens seem to be genetically polymorphic, the autoantibodies are inhibitory, and the autoepitopes are generally conserved among species. Anti-P450 autoantibodies share these characteristics with other autoantibodies, for example, antinuclear antibodies in @entity1252 . The identification of P450s as @entity1 autoantigens is clinically important. Diagnostic tests will be developed on the basis of cloned antigen, facilitating a better diagnosis of drug-induced and @entity775 . It is unknown what triggers autoantibody production against @entity12325 proteins. Furthermore, their pathogenetic role and thus their involvement in tissue destruction is unclear. In this context LKM1 autoantibodies may serve as a model. Although LKM1 antibodies are inhibitory, all LKM1 antibody-positive @entity1 tested so far are extensive metabolizers for drug metabolism mediated by P450IID6 and express this protein in their livers. Thus, the inhibitory LKM1 autoantibody does not sufficiently penetrate through the intact liver cell membrane to inhibit enzyme function in vivo. Presumably, tissue destruction in @entity775 is mediated by liver-infiltrating T lymphocytes. T lymphocytes have been cloned from liver tissue that specifically proliferate in the presence of recombinant cytochrome P450IID6. The construction of overlapping cDNA subclones is also valuable to identify immunodominant B cell as well as relevant T cell epitopes.

title: Identification of XXXX @entity12325 s as autoantigens.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['inflammatory liver diseases']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['systemic lupus erythematosus']

entities_list: @entity775 :: ('MESH:D019693', 'Disease') :: ['idiopathic autoimmune hepatitis', 'autoimmune hepatitis']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: INTRODUCTION: @entity6086 ( @entity15383 ) microcapsules were synthesized for use in controlled release. The aim of this study was to evaluate the @entity137 , antibacterial properties, and influence on gene expression of bone-related markers of 2 different formulas of @entity15383 microcapsules. METHODS: Two formulas of @entity15383 microcapsules (A and B) were evaluated, and pure @entity15383 powder was used as a positive control. The shell material of formula A was pure EC, and the PLA/EC blend of 1:1 was used as the shell material for formula B. The MG63 cells/Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) were used to evaluate the @entity137 , and the colony-forming units of @entity797 were monitored for the antibacterial effect. The relative messenger RNA expression of collagen I and osteocalcin was determined by real-time polymerase chain reaction. RESULTS: Both formulas of the @entity15383 microcapsules showed no @entity137 in MG63 cells; however, the @entity15383 positive control did exhibit @entity137 . The antibacterial effect of the 2 microcapsule formulas lasted longer than the positive control, and formula A lasted longer than formula B. For both @entity15383 microcapsule formulas, the relative messenger RNA expression of collagen I and osteocalcin was prolonged and up-regulated. The time effects of the influence on messenger RNA expression of collagen I and osteocalcin were different between the 2 microcapsule formulas. CONCLUSIONS: @entity15383 microcapsules had prolonged antibacterial activity and prolonged the up-regulation of bone-related markers with reduced @entity137 .

title: The biological performance of XXXX -loaded microcapsules.

entities_list: @entity797 :: ('1351', 'Species') :: ['Enterococcus faecalis']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

entities_list: @entity6086 :: ('MESH:D002126', 'Chemical') :: ['Calcium hydroxide']

answer: @entity6086 :: (MESH:D002126,Chemical) :: ['calcium hydroxide']


abstract: OBJECTIVE: To determine the value of repeat liver resection for recurrent colorectal metastases to the liver. SUMMARY BACKGROUND DATA: Liver resection represents the best and a potentially curative treatment for metastatic @entity14 . After resection, however, most @entity1 develop recurrent disease, often isolated to the liver. METHODS: This study reports the combined experience of repeat liver resection for recurrent liver metastases at an American and a European surgical oncology center. @entity1 were identified from prospective databases and records were retrospectively reviewed. A total of 126 @entity1 (American n = 96, 1986-2001; European n = 30, 1985-1999) underwent repeat liver resection. @entity1 characteristics were similar in the two institutions. Median follow-up from first liver resection was 88 and 105 months, respectively. RESULTS: Operations performed included 90 minor resections and 36 resections of a lobe or more. The 1-, 3-, and 5-year survival rates were 86%, 51%, and 34%. There were 19 actual 5-year survivors to date. By multivariate regression analysis (proportional hazard model), more than one lesion and @entity5 size larger than 5 cm were independent prognostic indicators of reduced survival. The interval between the first and second liver resection was not predictive of outcome. CONCLUSIONS: Repeat liver resection for @entity14 is safe. @entity1 with a low @entity5 load are the best candidates for a repeat resection. In well-selected @entity1 , further resection of the liver can provide prolonged survival after recurrence of @entity14 .

title: Second liver resections are safe and effective treatment for recurrent hepatic metastases from XXXX : a bi-institutional analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Patient']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal liver metastases', 'colorectal cancer to the liver']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: OBJECTIVE: To understand the clinical characteristics of @entity3001 in @entity1 . METHODS: Case records of 30 @entity1 with @entity3001 who were admitted to the pediatric department of Forest Hospital, Inner Mongolia from May 1995 to Oct. 2000, were reviewed. Twenty-one cases were male and 9 were female. Their age ranged from 2 to 14 years. The possible factors associated with the onset, incubation period, clinical manifestations of the organ systems and response to treatment were analyzed. RESULTS: Each of the 30 cases had a history of tick bite for one time or more. The incubation period was 1 to 14 days. All of them were hospitalized for typical @entity8831 . Among the 30 cases, 21 (70%) showed symptoms of @entity1729 ; 4 (13%) showed circulatory system symptom and manifestations of @entity296 ; 3 (10%) had joint @entity158 ; 1 case (3%) had eye symptom and another case (3%) had nervous system symptoms, such as @entity10 , @entity391 , @entity135 and so on. EEG and spinal fluid test showed some abnormal results. All the 30 cases were positive for IgG antibody to Lyme spirochetes with titers higher than 1:128. @entity114 or @entity7048 was effective in treatment of the @entity1 . CONCLUSION: The incubation period of the disease observed among this series of @entity1 was 1-14 d. @entity3001 in this group of @entity1 involved multiple organ systems while @entity8831 and @entity4841 were the most frequently seen manifestations. Most of the @entity1 had a favorable outcome with no sequelae.

title: [Clinical manifestations of 30 cases with XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['drowsiness, neck stiffness']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial lesion']

entities_list: @entity3001 :: ('MESH:D008193', 'Disease') :: ['Lyme disease']

entities_list: @entity7048 :: ('MESH:D002437', 'Chemical') :: ['cefazolin']

entities_list: @entity114 :: ('MESH:D010406', 'Chemical') :: ['Penicillin']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity8831 :: ('MESH:C538499', 'Disease') :: ['erythema migrans']

entities_list: @entity1729 :: ('MESH:D012141', 'Disease') :: ['acute upper respiratory tract infection']

entities_list: @entity4841 :: ('MESH:D018771', 'Disease') :: ['arthralgia']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

answer: @entity3001 :: (MESH:D008193,Disease) :: ['Lyme disease']


abstract: OBJECTIVES: Continuous wound infusion of local anaesthetics has been successfully applied for @entity282 control in several procedures but, surprisingly, it is underused in thoracic surgery. We aimed to investigate the effects of wound @entity1337 associated with systemic @entity1 -controlled @entity1337 in @entity1 undergoing @entity2 resection with muscle-sparing thoracotomy. METHODS: Sixty consecutive @entity1 undergoing @entity2 resection via standard muscle-sparing thoracotomy were randomized into two groups (wound @entity1337 and placebo groups). @entity1341 in the wound group and free-saline solution in the placebo group were injected using a multiholed catheter connected to an elastomeric pump inserted at the end of operation between the pericostal sutures and the serratus muscle and removed 48 h after. The inter-group differences were assessed by the following criteria: (i) level of cytokines [ @entity650 , @entity688 and @entity5 necrosis factor-alpha ( @entity310 )]; (ii) @entity158 on a visual analogue scale at rest and after coughing; (iii) recovery of respiratory functions (flow expiratory volume in 1 s % and forced vital capacity %) and (iv) narcotic medication consumption at different time points of the postoperative course. RESULTS: Five out of a total of 60 @entity1 were excluded from the final analysis. Thus, the wound and placebo groups comprised 27 and 28 @entity1 , respectively. The wound group compared with the placebo group had a significant decrease of @entity650 (P < 0.001), @entity688 (P < 0.001) and @entity310 (P < 0.001) blood concentration levels, @entity158 scores at rest (P < 0.001) and after coughing (P = 0.01), and a reduction of additional @entity1286 intake (P = 0.03) and Ketorolac (P = 0.01) during the entire postoperative course. The recovery of the flow expiratory volume in one second % (P = 0.01) and the forced vital capacity % (P = 0.02) was also better in the wound than in the placebo group. CONCLUSIONS: Our data prove that wound @entity1337 is an effective, easy and safe procedure. It significantly reduces systemic inflammatory markers, @entity158 scores and opioid intake; and accelerates the recovery of respiratory function. Catheter placement does not require particular manoeuvres by the surgeon nor does the elastomeric pump need any adjustment or care by physicians or nurses.

title: Efficacy of wound XXXX for controlling post-thoracotomy @entity158 : a randomized double-blind study   .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity1341 :: ('MESH:D002045', 'Chemical') :: ['Bupivacaine']

entities_list: @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['postoperative pain']

answer: @entity1337 :: (MESH:D000699,Disease) :: ['analgesia']


abstract: The endothelial cell protein C (PC) receptor ( @entity25698 ) facilitates PC activation by the thrombin-thrombomodulin complex. A soluble form of this receptor (sEPCR) found in plasma inhibits both activated PC (aPC) activity and PC activation by competing for PC with membrane-associated @entity25698 . Elevated sEPCR levels are found in approximately 20% of healthy subjects, but the mechanisms underlying this interindividual variability are unknown. We measured sEPCR levels in 100 healthy male volunteers, and observed 2 phenotypic groups of subjects. The temporal stability of sEPCR levels suggested genetic control. Extensive analysis of the @entity25698 gene in these subjects revealed 13 polymorphisms in complete linkage disequilibrium; these defined 3 haplotypes, 1 of which (A3) was strongly associated with high sEPCR levels. The high constitutive sEPCR levels observed in A3 haplotype carriers might reduce the efficiency of the PC system and predispose these subjects to @entity49 . By studying 338 @entity1 with @entity49 and 338 age- and sex-matched healthy subjects, we found that the A3 haplotype was overrepresented in the @entity1 . In multivariate analysis, subjects carrying the A3 haplotype had an increased risk of @entity715 (odds ratio [OR] = 1.8; P =.004). Thus, the A3 haplotype, which is associated with elevated plasma sEPCR levels, is a candidate risk factor for @entity49 .

title: A haplotype of the @entity25698 gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity49 :: ('MESH:D019851', 'Disease') :: ['venous thrombosis']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

answer: @entity715 :: (MESH:D013927,Disease) :: ['thrombosis']


abstract: AIMS: Dietary @entity844 profile, independent of caloric percent of fat, is a major regulator of body adiposity. This study examined the effects of dietary fat amount and types on fat storage and hypothalamic gene expression in the @entity19 model of chronic diet-induced @entity28 . METHODS: The dietary interventions were in twofold: (1) the @entity28 was induced by a 13-week obesogenic fat diet compared with a low-fat (LF) diet, and (2) the reversibility was tested by using high n-3 polyunsaturated fat ( @entity5204 ) and LF diets. Fifty-four C57Bl/6 @entity19 were fed a high-fat (59% in kcal) diet for 13 weeks and then classified as diet-induced @entity28 (DIO) or diet-resistant (DR) @entity19 according to upper and lower tertiles of body @entity1017 . The DIO @entity19 were then subdivided into three groups for a 6-week secondary dietary intervention. Two of the groups were switched to either a high n-3 @entity5204 (DIO-n3) or a low-fat (10% in kcal, DIO-LF) diet, whereas the third (controls) and DR @entity19 continued on the initial high-fat diet. Food efficiency was calculated as weekly body @entity1017 per gram of food intake. RESULTS: After switching the DIO @entity19 to the n-3 @entity5204 or LF diet, their body weights were reduced to the level of the DR and LF @entity19 . The food efficiencies were, from the highest to lowest, in the order: DIO>LF>DR>DIO-LF>DIO-n3. Using quantitative in situ hybridization, we found that the DIO @entity19 had higher levels of @entity18070 (LR, +290%, p<0.005) and @entity32327 (NPY, +25%, p<0.05) mRNA expression in the hypothalamic arcuate nucleus (Arc) than the DR @entity19 , whereas the level of @entity11982 ( @entity11982 ) mRNA expression was significantly reduced (-45%, p<0.01). All effects that were essentially returned to DR levels by the change to the n-3 @entity5204 diet and, with the exception of a failure to normalize Arc NPY mRNA levels, by the change to LF diet. CONCLUSIONS: Taken together, the present results show that both change in level and quality of dietary fat can potently alter hypothalamic neuropeptide expression and result in effective amelioration of diet-induced @entity28 . Interestingly, the n-3 @entity5204 diet when fed to already @entity28 @entity19 produced a pattern of hypothalamic gene expression similar to that in @entity28 resistant (DR) @entity19 . It remains to be determined if the effects of n-3 @entity1718 on brain neuropeptide gene expression are direct or indirect.

title: Role of fat amount and type in ameliorating diet-induced @entity28 : insights at the level of hypothalamic arcuate nucleus @entity18070 , @entity32327 and XXXX mRNA expression.

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity']

entities_list: @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

answer: @entity11982 :: (18976(Tax:10090),Gene) :: ['pro-opiomelanocortin']


abstract: Clinicopathological and immunohistochemical studies were performed in a @entity1 with @entity8231 limbic @entity198 , @entity4685 , @entity16 and @entity2746 secondary to @entity151 . A 67-year-old male smoker developed orthostatic dizziness 6 months prior to admission. Over the following months, his wife noticed that he became forgetful and confused. Over the next three weeks, he became unable to sit or stand unaided and admitted to our service. On admission, he was lethargic and disoriented in time and place. Neurological examination revealed marked @entity425 with distal dominant @entity2057 . A chest radiograph demonstrated a mass in the right middle lobe and a bronchial biopsy revealed @entity4153 . CT scan and MRI of the brain revealed abnormalities in the bilateral medial temporal lobes and putamen. He was treated with anti- @entity5 chemotherapy, but died of @entity1576 after 13 months illness. Postmortem examination showed a mass in the right middle lobe of the lung. No @entity5 metastases were noted in the nervous tissue. Microscopical examinations of the nervous system revealed @entity528 , astrogliosis and perivascular and @entity2617 in the hippocampus, subiculum, amygdala, putamen, medulla oblongata, spinal cord and dorsal root ganglia. Loss of Purkinje cells was also seen in the cerebellum without lymphocytic infiltration. Immunohistochemical analysis of the patient's serum and CSF by the use of adult @entity35 brain revealed immunoreactivity at the hippocampal pyramidal neurons @entity1251 and @entity16711 . At the higher dilution, neuronal nuclei were specifically stained.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [A clinicopathological study of a @entity1 with @entity8231 limbic @entity198 , XXXX , @entity16 and @entity2746 , associated with a unique antineuronal antibody].

entities_list: @entity2057 :: ('MESH:D009133', 'Disease') :: ['muscle atrophy']

entities_list: @entity198 :: ('MESH:D004660', 'Disease') :: ['encephalitis']

entities_list: @entity4153 :: ('MESH:D018288', 'Disease') :: ['a small cell carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity2617 :: ('MESH:D017254', 'Disease') :: ['parenchymatous lymphocytic infiltration']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['sensory neuropathy']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['limb weakness']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory failure']

entities_list: @entity8231 :: ('MESH:D010257', 'Disease') :: ['paraneoplastic']

entities_list: @entity151 :: ('MESH:D055752', 'Disease') :: ['small cell lung cancer']

entities_list: @entity2746 :: ('MESH:D013132', 'Disease') :: ['cerebellar degeneration']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal loss']

answer: @entity4685 :: (MESH:D009187,Disease) :: ['myelitis']


abstract: Mesothel is the cell lining of serosal surface of the pleura, peritoneum, pericardium, and testis. @entity3620 is a highly aggressive @entity5 from mesothel that has a tendency to grow rapidly and invade locally. Although the incidence of malignant mesenterial mesothelioma is not so high, the case fatality rate is very high. The aim of this case report is to report the rare and difficult case with several complications. A Balinese @entity1 , 64 years old, came with chief complaint of @entity425 , @entity1625 , and @entity390 , with history of previous @entity409 . On physical examination were found a decrease of conciousness, subfebrile, abdominal distension, @entity843 , negative traube space, and paralysis of the left side of the body. Laboratory examination results showed @entity491 , @entity417 , trombocytosis, @entity4988 , increase of alkaline phosphatase, and mild @entity2753 . Abdominal USG showed intraperitoneal mass which some of them attach to abdominal wall, possibly from mesenterium and @entity843 , esophagogastroduodenoscopy (EGD) revealed @entity354 and anthral erossive @entity3621 , skull CT scan showed small @entity1188 at left parietal medulla and right basal ganglia, cytology showed spreaded and grouped mesothel with reactive lymphocyte and amorph back ground. FNAB result showed @entity3620 , and normal colonoscopy. Based on the above data, the diagnoses were malignant mesenterial mesothelioma, @entity354 and anthral erossive @entity3621 , and non @entity64 . Malignant mesenterial mesothelioma should be considered in @entity1 with the combination of unexplained @entity843 and @entity490 . Although the result of treatment is very disappointing, the @entity1 had to be treated optimally to increase quality of life.

title: Malignant mesenterial mesothelioma in @entity64 XXXX .

entities_list: @entity1625 :: ('MESH:D004828', 'Disease') :: ['abdominal enlargement']

entities_list: @entity417 :: ('MESH:D000740', 'Disease') :: ['hypochromic-micrositic anemia']

entities_list: @entity4988 :: ('MESH:D034141', 'Disease') :: ['hypoalbuminemia']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['hemorrhagic stroke']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver disease']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['weakness']

entities_list: @entity2753 :: ('MESH:D007010', 'Disease') :: ['hyponatremia']

entities_list: @entity3620 :: ('MESH:C562839', 'Disease') :: ['Malignant mesothelioma', 'malignant mesothelioma']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarction']

entities_list: @entity3621 :: ('MESH:D005756', 'Disease') :: ['gastritis']

entities_list: @entity354 :: ('MESH:D005764', 'Disease') :: ['reflux esofagitis']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity491 :: ('MESH:D007964', 'Disease') :: ['leukocytosis']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: @entity63 may occur as a serious complication related to the use of femoral cannulation during veno-arterial cardiopulmonary support (CPS). We developed a simple cannula for femoral arterial cannulation with two holes in the side wall, which could provide the distal limb blood flow without additional cannulation or surgical procedure. This cannula can be inserted into the femoral artery by routine Seldinger technique. The distal blood flow from the side holes can be confirmed by Doppler detector without specialized techniques. In porcine experimental model, the distance between the position where the blood flow was first detected and those where the blood leakage took place was at least more than 10 mm. When this cannula and its side holes were adequately positioned, the mean distal limb flow ranged from 75 to 90 mL/min under CPS at a flow of 1.5 L/min. We employed this cannula for six @entity1 in clinical settings. Three @entity1 showed a good distal limb blood flow at the introduction position without its adjustment. The other three @entity1 showed @entity63 at the introduction position, but the @entity63 was soon recovered after a slight adjustment of its position. There was no blood leakage from the percutaneous entry into the artery in all cases. We currently use this cannula as the first choice for @entity1 undergoing a prolonged CPS.

title: A novel femoral arterial cannula to prevent XXXX during cardiopulmonary support: preliminary report of experimental and clinical experiences.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['Distal limb ischemia', 'distal limb ischemia', 'limb ischemia']

answer: @entity63 :: (MESH:D007511,Disease) :: ['limb ischemia']


abstract: Several mechanisms have been proposed to explain the electrocardiographic patterns observed during various forms of polymorphic @entity1165 , including @entity1166 . Such mechanisms include the coexistence of either multiple foci or multiple exit pathways from single foci giving rise to various forms of aberrant ventricular activation sequences. For example, the simultaneous firing of two widely spaced foci at slightly different frequencies has been used to explain the undulating electrocardiogram that is characteristic of @entity1166 . However, in spite of some supporting experimental evidence, such an idea remains conjectural from the clinical point of view. Here I discuss a mechanism that has been proposed recently to explain both monomorphic and polymorphic patterns (including undulating patterns) of @entity1165 . The hypothesis is derived from the theory of spiral wave activity in excitable media, and from recent experiments using high resolution optical mapping in isolated two-dimensional ventricular muscle preparations that demonstrate that spiral wave activity may account for self-sustaining reentrant activation. Such studies have led to the observation that the behavior of the spiral center, the core, plays a key role in determining the electrocardiographic manifestation of the @entity943 . Indeed, a stationary position of the core results in a monomorphic pattern of activation. On the other hand, beat-to-beat changes in the core position (i.e., drifting) leads to irregular patterns of activation. In fact, when drifting occurs in one direction, it gives rise to a Doppler shift in the excitation period in such a way that two coexisting frequencies are manifest, one ahead of and one behind the drifting core. The activation frequency in the region ahead of the core is always higher than that behind the core. Under such conditions, electrocardiographic recordings of the activity demonstrate an undulating pattern, which resembles that of @entity1166 . When the core drifts in various directions, a polymorphic pattern is manifest. Thus, depending on spiral core dynamics, monomorphic, undulating, or completely irregular patterns may be observed. Moreover, transitions between such patterns can also occur. For example, drifting spirals giving rise to polymorphic activation can become stationary and result in monomorphic activation as a result of anchoring of the core to a small discontinuity (e.g., an artery or small scar) in the tissue. Direct extrapolation of such results to clinical cases is not appropriate. However, the observations discussed in this article offer a new testable hypothesis in which a common mechanism is postulated for the electrocardiographic patterns associated with monomorphic and polymorphic @entity591 .

title: Spiral wave activity: a possible common mechanism for polymorphic and monomorphic XXXX .

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardias']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia']

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardias', 'ventricular tachycardia']

entities_list: @entity1166 :: ('MESH:D016171', 'Disease') :: ['torsades de pointes']

answer: @entity1165 :: (MESH:D017180,Disease) :: ['ventricular tachycardias']


abstract: INTRODUCTION: @entity3052 is characterized by accumulation of immature cells because of imbalance between proliferation and apoptosis. In @entity3052 , simultaneous expression of proliferative ( @entity7801 , @entity2467 ) and antiapoptotic genes ( @entity588 ), are unknown. @entity1 AND METHODS: We prospectively assessed proliferative and antiapoptotic gene  transcripts using Taqman probe chemistry in 48 @entity3052 @entity1 . A stepwise Cox regression model was applied for independent prognostic factors. RESULTS: Thirty-two of 48 (75%) @entity1 achieved complete remission. At  follow-up ranging from 0.5 to 57.3 months, event-free survival (EFS) was 26.9    6.3% (range, 15.5%-39.6%) and  @entity3012 34.5    7.46% (range, @entity19 %-48.9%). High white blood cell count correlated with an inferior complete remission rate (P  = .021). Cytogenetics and @entity7801 internal tandem duplication did not predict EFS or @entity3012 . The transcripts of @entity7801 , @entity2467 , and @entity588 showed a significant linear association with each other in Pearson correlation ( @entity7801 vs. @entity2467 : R  =  0.8234; P  < .001; @entity2467 vs. @entity588 : R  = 0.3377; P  = .01; @entity7801 vs. @entity588 : R  = 0.3815; P  = .007). In a validation cohort (Microarray Data Set GSE1159) of @entity3052 @entity1 , the global gene expression profile depicted a similar interrelationship. @entity1 with a greater platelet count were associated with increased transcript levels of @entity588 (P  =  .034). In univariate analysis, a high transcript level of @entity7801 and high transcript ratio of @entity7801 / @entity588 and @entity7801 and @entity2467 / @entity588 significantly predicted @entity3012 (P  = .043, .028, and .028, respectively). In a stepwise Cox regression model, high @entity7801 and @entity2467 / @entity588 ratio predicted @entity3012 (HR, 2.29). CONCLUSION: To our knowledge, this is the first study that evaluated proliferative and antiapoptotic transcripts simultaneously, and results have shown that it is the relative levels of these transcripts that determine outcome in @entity3052 @entity1 rather than their expression in isolation.

title: Relative Receptor Tyrosine Kinases and Anti-Apoptotic Transcripts Hold Potential for Predicting Inferior Outcome in XXXX : A Prospective Pilot Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['adult AML', 'Acute myeloid leukemia', 'AML']

answer: @entity3052 :: (MESH:D015470,Disease) :: ['Adult Acute Myeloid Leukemia']


abstract: BACKGROUND _ AIMS: IgG4-related sclerosing @entity255 and type 1 autoimmune @entity788 (IgG4-SC/ @entity6052 ) are characterized by massive lymphoplasmacytic infiltration including Th2 and regulatory T cells (Tregs). This study was conducted to address which chemotactic factors are involved in this condition. METHODS: Chemokine expression profiles in tissue were examined in IgG4-SC/ @entity6052 (n=17), classical @entity991 (IgG4(low) PSC, n=17), PSC with elevated serum/tissue IgG4 levels (IgG4(high) PSC, n=5), and @entity2835 (n=7). We focused on five chemotactic factors/receptors ( @entity38458 - @entity9235 , @entity14420 / @entity14421 - @entity16952 ), given that @entity16952 and @entity9235 are predominantly expressed in both Th2 and Tregs. RESULTS: In conjunction with higher expression levels of @entity3646 and @entity688 , expression values of @entity38458 and @entity9235 transcripts were significantly higher in IgG4-SC/ @entity6052 than in IgG4(low) PSC (p=0.002) and IgG4(high) PSC (p=0.023). @entity38458 and @entity9235 were also overexpressed in IgG4(high) PSC than in IgG4(low) PSC (p=0.023). No difference was seen for @entity14420 , @entity14421 , and @entity16952 . In situ hybridization revealed @entity38458 to be predominantly expressed in the pancreatic duct epithelium, peribiliary glands, and vascular endothelial cells including the ones involved in obliterative @entity3527 in IgG4-SC/ @entity6052 , in contrast to IgG4(high) PSC where this chemotactic factor was positive in several infiltrating lymphocytes. These @entity38458 -expressing sites were infiltrated by @entity9235 (+) lymphocytes. On immunohistochemistry, @entity9388 (+) Th2 lymphocytes and @entity403 (+) Tregs were significantly larger in number in IgG4-SC/ @entity6052 , with the @entity9388 (+)/T-bet(+) cell ratio to be shifted in favour of Th2 in periductal and perivascular areas. CONCLUSIONS: @entity38458 - @entity9235 interaction may play a critical role in lymphocytic recruitment in IgG4-SC/ @entity6052 , leading to duct-centred @entity32 and obliterative @entity3527 .

title: Possible involvement of @entity38458 - XXXX interaction in lymphocytic recruitment in IgG4-related sclerosing @entity255 .

entities_list: @entity2835 :: ('MESH:D008105', 'Disease') :: ['primary biliary cirrhosis']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity991 :: ('MESH:D015209', 'Disease') :: ['primary sclerosing cholangitis']

entities_list: @entity3527 :: ('MESH:D010689', 'Disease') :: ['phlebitis']

entities_list: @entity255 :: ('MESH:D002761', 'Disease') :: ['cholangitis']

answer: @entity9235 :: (1237,Gene) :: ['CCR8']


abstract: OBJECTIVE: To evaluate the efficacy of systemic and intraarticular adenoviral transfer of a modified @entity5 necrosis factor alpha receptor (TNF alphaR) gene and its expression in @entity35 @entity1753 ( @entity1753 ). METHODS: @entity35 with @entity1753 received injections of replication-deficient adenovirus containing either a @entity35356 ( @entity35356 ) gene or a control beta-galactosidase (beta-gal) gene. The @entity35356 gene codes for a fusion protein consisting of the @entity1 55-kd TNF alphaR and a mouse IgG heavy chain. Successful gene transfer was determined by serum TNF alphaR measurements and by histologic examination of injected joints with in situ blue staining. RESULTS: Serum TNF alphaR levels were detectable for 8 days following systemic @entity35356 gene transfer. @entity1753 severity was significantly suppressed by @entity35356 gene transfer, both prior to and following @entity625 onset (P = 0.0001, by repeated-measures 2-factor analysis of variance). Direct synovial @entity35356 gene transfer was successful, but induced an inflammatory response without any net @entity35356 benefit. CONCLUSION: Systemic adenoviral-mediated transfer of the @entity35356 gene suppressed @entity1753 during its transitory expression. Intraarticular gene transfer was limited by an @entity603 that was not overcome by delivery of the @entity35356 gene. @entity35356 is an excellent protein candidate for further therapeutic study.

title: Suppression of @entity1753 through adenovirus-mediated transfer of a modified XXXX necrosis factor alpha receptor gene.

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis']

entities_list: @entity1753 :: ('MESH:D001169', 'Disease') :: ['collagen-induced arthritis', 'CIA']

entities_list: @entity603 :: ('MESH:D013585', 'Disease') :: ['adenoviral synovitis']

entities_list: @entity35356 :: ('MESH:C537777', 'Disease') :: ['TNFI', 'TNF alpha inhibitor']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: OBJECTIVE: To compare the acute and chronic effects of @entity594 retard ( @entity5563 ), @entity594 gastrointestinal therapeutic system (NGITS) and @entity3591 at trough and peak plasma concentrations of drug on blood pressure and heart rate, and on plasma @entity1063 and @entity1425 levels in @entity1 with mild-to-moderate @entity101 (diastolic blood pressure 95-115 mmHg). DESIGN AND METHODS: After 3-4 weeks' placebo treatment, @entity1 of both sexes were randomly allocated to be administered 10 or 20 mg @entity5563 twice a day, 30 or 60 mg NGITS once a day, and 5 or 10 mg @entity3591 once a day for 6 weeks. Initially, for the first 2 weeks, the lowest dose of each drug was used, but higher doses were administered after 2 weeks if sitting diastolic blood pressure was > 90 mmHg. @entity1 were evaluated after administration of the first dose and after 6 weeks' therapy in a hospital setting. Blood samples were taken for high-performance liquid chromatography measurement of @entity2922 and drug levels at various intervals for a period covering trough to peak drug level ranges. RESULTS: Administration of all three drugs reduced clinic blood pressure to the same level after 6 weeks' therapy, but heart rate was increased slightly only with @entity3591 (P < 0.05). Administration of @entity5563 reduced blood pressure more abruptly whereas administrations of NGITS and @entity3591 induced smoother falls after acute and chronic treatments: a significant increase in heart rate was observed with @entity3591 after chronic treatment. Both acute and chronic treatments with @entity5563 (n = 19) increased @entity1063 levels (P < 0.01) transiently (2-4 h). In contrast, administration of NGITS (n = 22) did not increase @entity1063 levels and even induced a slight but significant decrease in @entity1063 levels 5-6 h after chronic treatments. Although administration of @entity3591 (n = 22) did not increase @entity1063 levels transiently either after acute or after chronic administration, it did induce a sustained rise in basal @entity1063 levels by more than 50% after chronic therapy (P < 0.01). Plasma @entity1425 levels were not increased by any of the treatments and even a slight decrease was observed 4 h after administration of a dose following chronic treatments with NGITS and @entity3591 (P < 0.05). CONCLUSIONS: The transient increase in @entity1063 levels observed with @entity5563 and the sustained increases in @entity1063 levels observed after chronic treatment with @entity3591 suggest that sympathetic activation occurs with those two drugs. The lack of increase in @entity1063 levels after administration of NGITS suggests that this formulation does not activate the sympathetic system. The lowering of @entity1425 levels after administrations of NGITS and @entity3591 suggests that inhibition of release of @entity1425 by the adrenal medulla occurs with longer-acting @entity7236 formulations.

title: Different effects of @entity594 and @entity3591 on circulating XXXX levels in essential @entity101 @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity7236 :: ('MESH:C038806', 'Chemical') :: ['dihydropyridine']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity1425 :: ('MESH:D004837', 'Chemical') :: ['epinephrine']

entities_list: @entity3591 :: ('MESH:D017311', 'Chemical') :: ['amlodipine']

entities_list: @entity2922 :: ('CHEBI:33567', 'Chemical') :: ['catecholamine']

entities_list: @entity594 :: ('MESH:D009543', 'Chemical') :: ['nifedipine']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

answer: @entity2922 :: (CHEBI:33567,Chemical) :: ['catecholamine']


abstract: BACKGROUND AND AIMS: 66,000 @entity1 and adolescents are treated at emergency departments (EDs) in England and Wales each year for @entity130 . The aim of this study was to compare adolescent @entity130 rates in cities and towns and determine how @entity130 varies with @entity1949 and gender. METHODS: The study was set in three cities in Wales, UK, and their surrounding towns. Subjects were 11-17 year olds treated for @entity130 at one of seven EDs from 1 October 2005 to 30 September 2006. Area of residence (electoral divisions, EDivs) was identified from @entity1 postcode. EDivs were aggregated into @entity1949 fifths for males and females and cities and towns. @entity130 rates, rate ratios and 95% CIs were calculated. RESULTS: 1472 @entity1 and adolescents of 11-17 years old were treated for @entity130 . Male city @entity130 rates were 14.2/1000 11-17 year olds; and 13.1 in towns. Female city @entity130 rates were 6.0; and 5.6 in towns. In the most deprived city areas males had @entity130 .6 times (95% CI 1.85 to 3.59) that of the most affluent, compared with 2.0 times in towns (95% CI 1.39 to 2.86). For females, the most deprived city areas had @entity130 rates 5.3 times that of the most affluent (95% CI 2.93 to 9.41), compared with 2.8 times in towns (95% CI 1.47 to 5.28). CONCLUSIONS: @entity130 increased with increasing @entity1949 in cities and their feeder towns. This was true for @entity1 and @entity1 , though rates for @entity1 were consistently higher. This link between @entity130 and @entity1949 was stronger for @entity1 in cities than in feeder towns. Strategies to prevent youth violence need to include improved safeguarding arrangements for @entity1 living in the most deprived city areas.

title: The impact of XXXX on youth violence: a comparison of cities and their feeder towns.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patient', 'boys', 'girls']

entities_list: @entity1949 :: ('MESH:D012892', 'Disease') :: ['deprivation']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['Injury in youth violence', 'assault injury rates 2', 'Assault injury', 'assault injury']

answer: @entity1949 :: (MESH:D012892,Disease) :: ['deprivation']


abstract: BACKGROUND: Qualitative alterations or abnormal expression of microRNAs (miRNAs) in @entity694 have mainly been demonstrated in @entity5 . Poorly overlapping sets of oncomiRs, @entity5 suppressor miRNAs and metastamiRs have been linked with distinct stages in the progression of @entity14 . To identify changes in both miRNA and gene expression levels among normal colon mucosa, @entity5 and liver @entity3 samples, and to classify miRNAs into functional networks, in this work miRNA and gene expression profiles in 158 samples from 46 @entity1 were analysed. RESULTS: Most changes in miRNA and gene expression levels had already manifested in the @entity5 while these levels were almost stably maintained in the subsequent @entity5 -to- @entity3 transition. In addition, comparing normal tissue, @entity5 and @entity3 , we did not observe general impairment or any rise in miRNA biogenesis. While only few mRNAs were found to be differentially expressed between primary @entity14 and liver @entity3 , miRNA expression profiles can classify @entity5 and @entity3 well, including differential expression of @entity17308 , @entity10018 and @entity50691 . Of 82 miRNAs that were modulated during @entity5 progression, 22 were involved in EMT. qRT-PCR confirmed the down-regulation of @entity6529 and @entity17308 in both @entity5 and @entity3 compared to normal mucosa and of @entity6991 in @entity3 compared to @entity5 . The upregulation of miR-201 in @entity3 compared both with normal and primary @entity5 was also confirmed. A preliminary survival analysis considering differentially expressed miRNAs suggested a possible link between @entity17308 expression in @entity3 and @entity1 survival. By integrating miRNA and target gene expression data, we identified a combination of interconnected miRNAs, which are organized into sub-networks, including several regulatory relationships with differentially expressed genes. Key regulatory interactions were validated experimentally. Specific mixed circuits involving miRNAs and transcription factors were identified and deserve further investigation. The suppressor activity of @entity21175 on @entity61450 gene was identified for the first time and confirmed in an independent set of samples. CONCLUSIONS: Using a large dataset of CRC miRNA and gene expression profiles, we describe the interplay of miRNA groups in regulating gene expression, which in turn affects modulated pathways that are important for @entity5 development.

title: Impact of microRNAs on regulatory networks and pathways in XXXX @entity14 and development of @entity3 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour', 'tumor', 'primary tumors', 'primary tumor']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal carcinoma', 'colorectal cancer']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: UNASSIGNED: Our aim was to identify miRNAs that can predict risk of relapse in pediatric @entity1 with @entity981 ( @entity981 ). Following high-throughput miRNA expression analysis (48 samples), five miRs were selected for further confirmation performed by real time quantitative PCR on a cohort of precursor B-cell @entity981 @entity1 (n   =   138). The results were correlated with clinical parameters and outcome. Low expression of @entity16283 -151-5p, and @entity15851 , and high expression of @entity41177 or a combination of all three predicted inferior relapse free survival (P   =   0.007, 0.042, 0.025, and <0.0001, respectively). Cox regression analysis identified aberrant expression of the three miRs as an independent prognostic marker with a 10.5-fold increased risk of relapse (P   =   0.041) in PCR-MRD non-high risk @entity1 . Furthermore, following exclusion of @entity1 harboring @entity6763 deletion, the aberrant expression of all three miRs could identify @entity1 with a 24.5-fold increased risk to relapse (P   <   0.0001). The prognostic relevance of the three miRNAs was evaluated in a non-BFM treated precursor B-cell @entity981 cohort (n   =   33). A significant correlation between an aberrant expression of at least one of the three miRs and poor outcome was maintained (P   <   0.0001). Our results identify an expression profile of @entity16283 -151-5p, @entity15851 , and @entity41177 as a novel biomarker for outcome in pediatric precursor B-cell @entity981 @entity1 , regardless of treatment protocol. The use of these markers may lead to improved risk stratification at diagnosis and allow early therapeutic interventions in an attempt to improve survival of high risk @entity1 .    2015 Wiley Periodicals, Inc.

title: @entity16283 expression profiling at diagnosis predicts relapse in pediatric precursor B-cell XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL', 'acute lymphoblastic leukemia']

answer: @entity981 :: (MESH:D054198,Disease) :: ['acute lymphoblastic leukemia']


abstract: @entity453 is a recognized risk factor for symptomatic @entity64 but the influence on asymptomatic @entity64 has not been clearly determined. The purpose of this work was to determine the relationship between @entity301 and silent @entity4798 and the influence of vascular risk factors and @entity2998 in a representative sample of Spanish @entity1 with symptomatic @entity453 . A consecutive sample of 100 subjects with @entity583 , @entity951 or both were included in the survey. @entity1 with a potential source of emboli from the heart were excluded. As main baseline variables, we considered vascular risk factors; complete cardiological study, including coronary angiography; brain computed tomography (CT) to detect @entity1188 ; echo-Doppler of supra-aortic vessels to detect @entity850 ; and carotid angiography, when appropriate. As the outcome variable, we observed the incidence of symptomatic @entity64 after an 18 month mean follow-up. We found silent @entity4798 in 30 @entity1 (93% were of lacunar type). None of the vascular risk factors was related to @entity4798 either in univariate or multivariate analysis. Carotid @entity731 was the only significant predictor in a model of logistic regression (P < 0.0005), although the lesions were bilateral in the majority of cases. We observed a very low incidence of symptomatic @entity64 after a mean follow-up of 18 months. Silent @entity4798 are a frequent finding on brain CT in @entity1 with @entity301 and are associated with @entity2998 ; however, it does not seem to have important prognostic significance.

title: Silent XXXX in @entity1 with @entity301 . A Spanish population survey.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity4798 :: ('MESH:D020520', 'Disease') :: ['brain infarction', 'brain infarcts']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['ischaemic stroke', 'stroke']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary heart disease']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity2998 :: ('MESH:D002340', 'Disease') :: ['carotid atherosclerosis']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['Coronary artery disease', 'coronary artery disease']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

answer: @entity4798 :: (MESH:D020520,Disease) :: ['brain infarctions']


abstract: OBJECTIVES: This study was conducted to determine the frequency and significance of Coxsackie @entity22421 -specific immunoglobulin-M (IgM) in @entity1 with @entity1000 and compare them with the frequency in both unmatched and matched control subjects. BACKGROUND: The principal evidence supporting a pathoetiologic role for Coxsackie B viruses in @entity1 @entity384 is derived from retrospective serologic studies. These studies have evaluated @entity1 with end-stage disease and have failed to recognize the importance of assessing both matched and unmatched control subjects. METHODS: In this prospective case-control study, we assessed sera for Coxsackie @entity22421 -specific IgM (serotypes B1 to B5) from 114 @entity1 with @entity384 at diagnosis or referral to our center, 94 healthy unmatched control subjects, 41 healthy matched control subjects from the same general practitioner and 32 members of the @entity1 ' own households. RESULTS: A higher frequency of positive Coxsackie @entity22421 IgM was observed in @entity1 with @entity384 than in unmatched control subjects (33% vs. 5%; p = 3 x 10(-7)). In @entity1 with @entity384 , the response was monotypic (84%), commonly against serotypes B2 and B5, and was not associated with any clinical or histologic feature. The frequency of positive virus-specific IgM was similar in @entity1 with @entity384 and their 41 matched community control subjects (46% vs. 27%; p = 0.11) and 32 household contacts (37% vs. 28%; p = 0.59). Control subjects who tested positive for virus-specific IgM tended more commonly to be seropositive than did control seronegative subjects (community control subjects 37% vs. 18%, p = 0.32; household contacts 42% vs. 20%; p = 0.36) and had an identical serotypic response in 4 (33%) of 12 cases. CONCLUSIONS: The frequency of Coxsackie @entity22421 IgM was higher in @entity1 with @entity384 than in unmatched control subjects but was similar in @entity1 and control subjects who shared the same environment, indicating local spread of infection. The reason for the association between Coxsackie @entity22421 IgM and @entity384 and its relevance to pathogenesis remain to be established.

title: A prospective case-control study of antibodies to coxsackie @entity22421 in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity1000 :: ('MESH:C536277', 'Disease') :: ['idiopathic dilated cardiomyopathy']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['dilated cardiomyopathy']

answer: @entity1000 :: (MESH:C536277,Disease) :: ['idiopathic dilated cardiomyopathy']


abstract: @entity3494 contamination is a principal environmental health threat throughout the world. However, little is known about the effect of @entity3494 on steroidogenesis in granulosa cells (GCs). We found that the treatment of preovulatory GCs with @entity4250 stimulated @entity1420 production. A significant increase in serum level of @entity1420 was observed in female @entity35 following @entity4250 treatment at a dose of 10 mg/L/ @entity35 /day for 7 days. Further experiments demonstrated that @entity4250 treatment did not change the level of intracellular @entity1919 ( @entity268 ) or phosphorylated @entity2508 in preovulatory GCs; however, @entity1420 production was significantly decreased when @entity268 -dependent protein kinase (PKA) or @entity2508 pathway was inhibited. This implied that the effect of @entity4250 on @entity1420 production may require @entity268 /PKA and @entity2508 signaling but not depend on them. Furthermore, we found that @entity4250 decreased intracellular reactive @entity26 species (ROS) but increased the antioxidant @entity2041 ( @entity2197 ) levels and mitochondrial membrane potential (/\  m) in parallel to the changes in @entity1420 production. @entity1420 antagonist blocked the @entity3494 -stimulated increase of @entity2197 levels. @entity4250 treatment induced @entity4124 activation, although no apoptosis was observed. Inhibition of @entity4124 activity significantly decreased @entity1420 production stimulated by @entity4250 or follicle-stimulating hormone (FSH). @entity2197 depletion with @entity3016 led to cell apoptosis in response to @entity4250 treatment. Collectively, this study demonstrated for the first time that @entity4250 stimulates @entity1420 production through cleaved/active @entity4124 -dependent pathway, and the increase of @entity2197 level promoted by @entity1420 production may protect GCs against apoptosis and maintain the steroidogenesis of GCs in response to @entity4250 treatment.

title: @entity3494 induced @entity1420 production in a XXXX -dependent manner and changed redox status in preovulatory granulosa cells.

entities_list: @entity4250 :: ('MESH:C015001', 'Chemical') :: ['Arsenite', 'arsenite']

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone', 'Progesterone']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione']

entities_list: @entity1919 :: ('MESH:D000242', 'Chemical') :: ['cyclic AMP']

entities_list: @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague-Dawley rats']

entities_list: @entity3494 :: ('MESH:D001151', 'Chemical') :: ['arsenic', 'Arsenic']

entities_list: @entity3016 :: ('MESH:D019328', 'Chemical') :: ['buthionine sulfoximine']

answer: @entity4124 :: (25402(Tax:10116),Gene) :: ['caspase-3']


abstract: OBJECTIVE: To evaluate the impact of @entity1088 on aggressive behaviour and clinical outcomes in @entity1 and adolescents with @entity161 or @entity914 . METHODS: We reviewed the charts of 6 @entity1 and adolescents who were admitted consecutively to a long-term care facility for clinical outcomes, including seclusion and restraints incidents prior to and during @entity1088 treatment. We also present a representative case history. RESULTS: We noted clinically significant improvements in social interaction and decreases in the number of @entity2749 and homicidal or suicidal thoughts. The global assessment of functioning (GAF) scores improved significantly. Weight gain was significant. CONCLUSIONS: These cases illustrate the benefits of @entity1088 treatment in refractory childhood-onset @entity161 . Outcomes are similar to those described in adults. Even though open data limit conclusions from this study, it is pertinent that there was a clinically significant improvement in @entity146 . This may be particularly important for improved morale of @entity1 , their families, and treating staff. It may also be helpful in discharge to a less restrictive environment.

title: XXXX impact on clinical outcomes and @entity146 in severely ill adolescents with childhood-onset @entity161 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity1088 :: ('MESH:D003024', 'Chemical') :: ['clozapine']

entities_list: @entity2749 :: ('MESH:C580065', 'Disease') :: ['violent episodes']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive behaviours']

entities_list: @entity914 :: ('MESH:D011618', 'Disease') :: ['schizoaffective disorder']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

answer: @entity1088 :: (MESH:D003024,Chemical) :: ['Clozapine']


abstract: BACKGROUND AND STUDY AIM: Opiate or @entity1245 drugs are often used during colonoscopy, but they are associated with @entity1576 and prolonged recovery. @entity2607 , a tertiary anticholinesterase agent, is known to enhance @entity1337 and to reverse the central nervous system depressant effects of these drugs. This study compared the effect of giving @entity6882 alone with the effect of giving @entity6882 in combination with @entity2607 in @entity1 who were undergoing complete colonoscopy. @entity1 AND METHODS: A total of 44 outpatients undergoing elective colonoscopy were randomly assigned to receive @entity1337 with either @entity6882 0.5 mg/kg intravenously (group 1, n=24) or @entity2607 10 micrograms/kg intravenously, followed 5 minutes later by @entity6882 0.5 mg/kg intravenously (group 2; n=20). The @entity1 were assessed with regard to @entity26 saturation, hemodynamic changes, @entity158 perception and sedation scores, readiness to go home, and adverse effects. RESULTS: The group 1 @entity1 ' @entity26 saturations consistently fell, both during the procedure and in the recovery period; in group 2, @entity26 saturations remained stable throughout the procedure and recovery period (95.88%+/-0.99 vs. 98.15+/-0.99, P<0.001). @entity1 in group 2 reported lower @entity158 perception scores during the procedure (measured using a visual analog scale) than @entity1 in group 1 (1.46+/-0.31 vs. 1.75+/-0.41; F1,42=6.484, P<0.015) and were less sedated during recovery (F1,41=6.56, P<0.015). No significant differences were found between the two groups with regard to heart rate or arterial blood pressure. All @entity1 in group 2 were ready to go home after 25 minutes in the recovery area; three @entity1 in group 1 were not ready to leave at 25 minutes and left the facility after 60 minutes. Four @entity1 suffered from minor side effects of @entity2607 (sweating and @entity390 ). CONCLUSIONS: Combining @entity2607 with @entity6882 as preparatory treatment for @entity1 undergoing colonoscopy prevents @entity1576 , improves @entity1337 , and shortens recovery time, with only mild side effects.

title: Combining @entity2607 with XXXX for sedation and @entity1337 during colonoscopy.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia']

entities_list: @entity6882 :: ('MESH:D008614', 'Chemical') :: ['meperidine']

entities_list: @entity1245 :: ('MESH:D001569', 'Chemical') :: ['benzodiazepine']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory depression']

entities_list: @entity2607 :: ('MESH:D010830', 'Chemical') :: ['physostigmine', 'Physostigmine']

answer: @entity6882 :: (MESH:D008614,Chemical) :: ['meperidine']


abstract: PURPOSE: To monitor the biodistribution of @entity6527 aggregates upon subcutaneous (SC) and intravenous (IV) administration in @entity19 and measure their propensity to stimulate an early immune response. METHODS: A human mAb ( @entity6527 ) was fluorescently labeled, aggregated by agitation stress and injected in SKH1 @entity19 through SC and IV routes. The biodistribution of monomeric and aggregated formulations was monitored over 47  days by fluorescence imaging and the early immune response was measured by quantifying the level of relevant cytokines in serum using a Bio-plex assay. RESULTS: The aggregates remained at the SC injection site for a longer time than monomers but after entry into the systemic @entity12464 disappeared faster than monomers. Upon IV administration, both monomers and aggregates spread rapidly throughout the @entity12464 , and a strong accumulation in the liver was observed for both species. Subsequent removal from the @entity12464 was faster for aggregates than monomers. No accumulation in lymph nodes was observed after SC or IV administration. Administration of monomers and aggregates induced similar cytokine levels, but SC injection resulted in higher cytokine levels than IV administration. CONCLUSION: These results show differences in biodistribution and residence time between @entity6527 aggregates and monomers. The long residence time of aggregates at the SC injection site, in conjunction with elevated cytokine levels, may contribute to an enhanced immunogenicity risk of SC injected aggregates compared to that of monomers.

title: In vivo fluorescence imaging of @entity6527 aggregates after subcutaneous and intravenous injection in XXXX .

entities_list: @entity12464 :: ('MESH:D009360', 'Disease') :: ['circulation']

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: PURPOSE: @entity4562 is safe for the treatment of @entity1149 ( @entity1149 ), but some @entity1 experience @entity137 and require dose reduction. The purpose of this study was to evaluate the effect of @entity4562 dose reduction on survival. METHODS: We retrospectively analyzed 263 @entity1 with @entity1149 harboring sensitive @entity470 ( @entity470 ) mutation. All @entity1 had recurred or metastatic disease and received @entity4562 250  mg daily as palliative chemotherapy. RESULTS: Of the 263 @entity1 , 23 had @entity4562 dose reduction due to @entity137 (1 due to @entity33 , 5 due to @entity1910 , 11 due to hepatotoxicity and 6 for both skin and hepatotoxicity). In the dose reduction group, the mean dose intensity was 0.84 (range 0.48-0.98). @entity1 with dose reduction showed significantly prolonged progression-free survival (PFS) and @entity1349 ( @entity1349 ) compared to those receiving the standard dose (median PFS: 14.0 vs. 10.6  months, P  =  0.042, median @entity1349 : 54.5 vs. 29.6, P  =  0.020). In multivariate analysis, the effect of dose reduction was not significantly associated with prolonged PFS [hazard ratio (HR) 0.619, 95  % confidence interval (CI) 0.357-1.073, P  =  0.085], or @entity1349 (HR 0.625, 95  % CI 0.287-1.362, P  =  0.237). However, @entity1 receiving low-dose @entity4562 tended to have superior survival outcomes compared to those receiving standard-dose @entity4562 . CONCLUSIONS: The @entity1 experiencing @entity4562 dose reduction or short-term treatment interruption due to @entity137 did not show inferior survival, compared to those receiving full dose of @entity4562 in @entity1149 @entity1 with @entity470 mutation.

title: The @entity4562 dose reduction on survival outcomes in @entity470 mutant XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity4562 :: ('MESH:C419708', 'Chemical') :: ['gefitinib', 'Gefitinib']

entities_list: @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']